英夫利昔（inlfiximab）抗体ELISA试剂盒说明书

文档简介产品名称：英夫利昔（inlfiximab）抗体ELISA试剂盒型号：TR-Q-INFLIXIv2所属分类：土耳其matriks试剂盒价格：12000包装：96t生产地：土耳其样本量(l)10总时间(min)70测试样本Serum,plasma包装规格（T）96灵敏度(ng/mL)30回收率(%)97有效期(年)1Infliximab，注册商标为Remicade，中文名字为英利昔单抗、英夫利昔、因福利美、瑞米凯德、类克。英夫利昔单抗（Infliximab，Remicade）是一类相对新型的生物制剂。为高亲和性结合肿瘤坏死因子alpha(TNF-α)的嵌合体单抗，其被广泛应用于ZL自身免疫性疾病。因此，检测英夫利昔单抗、抗英夫利昔抗体血药浓度及水平在ZL和个性化用药上具有重要意义。MatriksBiotechnology专门生产针对抗体药的ELISA试剂盒，用于检测抗体药的体内浓度或因用该抗体药产生的抗体的体内浓度。MatriksBiotek,SHIKARI和KLONART为MatriksBiotechnology注册的产品商标。其产品达到ISO13485&CEIVD标准。英夫利昔(Infliximab，Remicade)ELISA(Specific)试剂盒英文名称：SHIKARIQS-INFLIXIELISAKIT；货号：TR-QS-INFLIXlv1；规格：96T英文描述：EnzymeimmunoassayforthequantitativedeterminationofInfliximab(Remicade)inserumandplasmaandotherbiologicalfluids中文描述：ELISA方法特异性定量测定血清、血浆或其他生物液体中的英夫利昔单抗(Infliximab，Remicade)的浓度SHIKARIQ-INFLIXIELISAKIT使用单克隆抗体高专一性结合血清、血浆或其他生物液中的英夫利昔单抗(Infliximab，Remicade)，是当前**一款用于定量检测英夫利昔(Infliximab，Remicade)体内浓度的特异性ELISA试剂盒。引用文献：#PEERREVIEWEDJOURNALARTICLES:1GibelliniL,DeBiasiS,BianchiniE,etal.Anti-TNF-αDrugsDifferentlyAffecttheTNFα-sTNFRSystemandMonocyteSubsetsinPatientswithPsoriasis.RichardY,ed.PLoSONE.11(12),2016.**4ChoiSY,KangB,LeeJH,ChoeYH.ClinicalUseofMeasuringTroughLevelsandAntibodiesagainstInfliximabinPatientswithPediatricInflammatoryBowelDisease.GutLiver.Sep92016.**6FarkasK.,etal.,EfficacyofinfliximabbiosimilarCT-P13inductiontherapyonmucosalhea领inulcerativecolitis.JournalofCrohn'sandColitisAdvanceAccesspublishedApril21,2016.7GutiérrezA,ZapaterP,JuanolaO,SempereL,GarcíaM,LavedaR,MartínezA,ScharlM,González-NavajasJM,SuchJ,WiestR,RoglerG,FrancésR.GutBacterialDNATranslocationisanIndependentRiskFactorofFlareatShortTerminPatientswithCrohn'sDisease.AmJGastroenterol.Apr;111(4):529-40,2016.8WonJaeSong,BenKang,SoYoonChoi,andYonHoChoe.AdalimumabTreatmentinPediatric-OnsetCrohn’sDiseasePatientsafterInfliximabFailure:ASingleCenterStudy.PediatrGastroenterolHepatolNutr.Jun;19(2):116122,2016.**9HayashiS,etal.,EarlyPrognosticFactorsAssociatedwiththeEfficacyofInfliximabTreatmentforPatientswithRheumatoidArthritiswithInadequateResponsetoMethotrexate.RheumatolTher(2016)3:155166**10BortlikM.,etal.,Discontinuationofanti-tumornecrosisfactortherapyininflammatoryboweldiseasepatients:aprospectiveobservation.ScandinavianJournalofGastroenterology,2016vol.51,no.2,196202.11Al-KarkhiM.A.,etal.,CorrelationbetweenAnti-infliximabandAnti-CCPAntibodiesDevelopmentinPatientswithRheumatoidArthritisTreatedwithInfliximabinBaghdadTeachingHospital.IOSRJournalofDentalandMedicalSciences,Volume14,Issue11Ver.IV(Nov.2015),PP95-100.**14JuanolaO.,etal.,Anti-TNF-alphalossofresponseisassociatedwithadecreasedpercentageofFoxP3+TcellsandavariantNOD2genotypeinpatientswithCrohn’sdisease.JGastroenterol(2015)50:758768.16MalíckovaK,etal.,Serumtroughinfliximablevels:AcomparisonofthreedifferentimmunoassaysforthemonitoringofCT-P13(infliximab)treatmentinpatientswithinflammatoryboweldisease,Biologicals2015.17FarkasK.etal,EfficacyofthenewinfliximabbiosimilarCT-P13inductiontherapyinCrohn’sdiseaseandulcerativecolitisexperiencesfromasinglecenter.ExpertOpin.Biol.Ther.15:(9)2015.18LeeY.M.etal,Infliximab‘‘Top-Down’’StrategyisSuperiorto‘‘Step-Up’’inMaintainingLong-TermRemissionintheTreatmentofPediatricCrohnDisease.JPGN60:(737743),2015.19Al-KarkhiM.A.,etal.,DevelopmentofAntibodiesagainstInfliximabinIraqiPatientswithRheumatoidArthritis.JFacMedBaghdad,57:(241-243),2015.**22Pallagi-Kunstár.etal.,UtilityofserumTNF-a,infliximabtroughlevel,andantibodytitersininflammatoryboweldisease.WorldJGastroenterol.20(17):(5031-5035),2014.**23KhannaR.,etal.,TherapeuticDrugMonitoringofTNFAntagonistsinInflammatoryBowelDisease.Gastroenterology&Hepatology,August(478-489),2014.**24KrajcovicovaA.etal.,Delayedhypersensitivityreactionafterinitialdoseofinfliximab:acasereport.EuropeanJournalofGastroenterology&Hepatology26:(485-487),2014.27BortlikM,etal,ImpactofAnti-TumorNecrosisFactorAlphaAntibodiesAdministeredtoPregnantWomenWithInflammatoryBowelDiseaseonLong-termOutcomeofExposedChildren.InflammBowelDis20:(495-451),2014.29GutierrezA,etal,GeneticsusceptibilitytoincreasedbacterialtranslocationinfluencestheresponsetobiologicaltherapyinpatientswithCrohn’sdisease,Gut0:19,2013.**30GrosenA.,etal,Infliximabconcentrationsinthemilkofnursingmotherswithinflammatoryboweldisease,JCrohnsColitis2013.**33BortlikMetal,“Pregnancyandnewbornoutcomeofmotherswithinflammatoryboweldiseasesexposedtoanti-TNF-atherapyduringpregnancy:three-centerstudy”,ScandinavianJournalofGastroenterology.48:951958,201334BortlikM,etal,InfliximabtroughlevelsmaypredictsustainedresponsetoinfliximabinpatientswithCrohn'sdisease,JournalofCrohn'sandColitis2012.**35MalickovaK,etal,Phosphatidylserine-dependentanti-prothrombinantibodies(aPS/PT)ininfliximab-treatedpatientswithinflammatoryboweldiseases,AutoimmunHighlights,2012.**36TakahashiH,etal,Plasmatroughlevelsofadalimumabandinfliximabintermsofclinicalefficacyduringthetreatmentofpsoriasis,JournalofDermatology2012;39:1-4.**37SeokLeeY,etal,“EfficacyofEarlyInfliximabTreatmentforPediatricCrohn’sDisease:AThree-yearFollow-up”,PediatricGastroenterology,Hepatology&Nutrition2012;15(4):243-249**38MolnarT,etal,“ImportanceoftroughlevelsandantibodytitersontheefficacyandsafetyofInfliximabtherapyininflammatoryboweldisease”,ZGastroenterol2012;50-A5339KatoS,etal,“ElevatedSerumIgEPriortoAcuteSevereInfusionReactionDuringInfliximabMaintenanceTherapyinaCrohn’sDiseasePatient”,Crohn’s&ColitisFoundationofAmerica201140AdisenE,etal,“Anti-infliximabantibodystatusanditsrelationtoclinicalresponseinpsoriaticpatients”:Apilotstudy,JournalofDermatology2010;37:708713.MatriksBiotechnology抗体药的药效及个体化应用专家抗体药是一类相对新型的生物制剂。检测抗体药及其抗体水平在ZL和个性化用药上具有重要意义。大量的临床和制药公司都在致力于抗体药物的浓度水平和LX的研究。Matriks生物技术公司专门生产针对抗体药的ELISA试剂盒，用于检测抗体药的体内含量或因用于产生的针对相应抗体药的抗体的体内含量。MatriksBiotek?,SHIKARI?和KLONART?为Matriks生物技术公司注册的产品商标。其产品达到ISO13485&CEIVD标准。Matriks生产用于检测抗体药在体内的浓度和LX的试剂盒主要针对如下几种抗体药。1.Infliximab注册商标为Remicade，由Schering-Plough生产，中文名字为英利昔单抗、英夫利昔、因福利美、瑞米凯德、类克。Infliximab为高亲和性结合肿瘤坏死因子alpha(TNF-α)的嵌合体单抗，其被广泛应用于ZL自身免疫性疾病。MatriksBiotekShikariInfliximabELISA使用单克隆抗体高专一性结合血清、血浆和其他生物液中的Infliximab，是当前**的一款用于定量检测Infliximab(Remicade?)体内含量的特异性ELISA试剂盒。2.Adalimumab注释商标为Humira,为AbbottLaboratories产品，中文名阿达木单抗、修美乐。Adalimumab为特异性结合TNF-α的人源性抗体，Adalimumab通过阻止TNF-α与其细胞表面受体相结合，发挥KY作用。MatriksBiotekshikari抗体检测抗Adalimumab抗体，用于检测ZL过程中抗Adalimumab抗体状况，为医师提供时机以减少抗Adalimumab抗体产生（例如添加免疫YZ性药物），以阻止抗体药失效。3.Etanercept商标为Enbrel和Altebrel，中文名依那西普，恩利.是一种干扰TNF-α、用于自身免疫性疾病ZL的生物药物。针对Etanercept的特异性单抗用于检测血样中Etanercept量。MatriksBiotekShikariQ-ETA是市面上用于定量检测Etanercept的ELISA试剂盒。4.人肿瘤坏死因子及受体MatriksBiotek开发的高敏感度、专一性TNF-α检测试剂盒，该试剂盒基于固定在固相面上的针对TNF-alpha的单抗和标记了马辣根过氧化物酶的另一单抗经三明治夹心法检测TNF-α。5.Bevacizumab商标名为Avastin?，由Genentech/Roche生产，中文名为阿瓦斯汀、贝伐单抗、安维汀、癌思停。Bevacizumab为血管生成YZ剂，在包括结肠和直肠癌、肺癌、乳腺癌、肾癌、卵巢癌等多种肿瘤中被批准使用。MatriksBiotekShikariQ-BEVAEnzymeImmunoassay用于检测血清或血浆中游离bevacizumab含量。以便保证其有效的血药浓度。6.Rituximab商标为Rituxan,Mabthera,Zytux，中文名为利妥昔单抗注射剂、美罗华、利妥昔单抗、利克散、贺普丁、莫瘤。Rituximab为针对B细胞表面抗原CD20蛋白的嵌合型单克隆抗体。Rituximab可破坏B细胞，从而用于ZL包括多种白血病、淋巴瘤、移植排斥和自身免疫失调性疾病等多种因B细胞过量、B细胞高反应性和B细胞功能失调引起的疾病。Rituximab的使用可引起机体产生相应抗体。MatriksBiotekRituximab-ELISA和Rituximab抗体分别用于测定机体内rituximab及其抗体的水平，从而为维持有效rituximab的血药浓度和提供抗抗体措施提供预防性举措。7.Trastuzumab商标名为Herclon,Herceptin，中文名为赫赛汀、癌平、曲妥珠单抗。Trastuzumab为干扰HER2/neu受体的单克隆抗体，其主要用于乳腺癌的ZL。Trastuzumab的使用可导致机体产生抗Trastuzumab抗体。MatriksBiotekTrastuzumab-ELISA和抗体分别用于检测机体trastuzumab和其抗体的浓度。MatriksBiotek抗体药个性化用药测试盒产品目录中文名称英文名称货号规格Infliximab，商标Remicade，英利昔单抗、英夫利昔、因福利美、瑞米凯德、类克英夫利昔单抗（类克）ELISA试剂盒SHIKARIQS-INFLIXIELISAKITTR-QS-INFLIXIv196T英夫利昔单抗（类克）ELISA试剂盒SHIKARIQ-INFLIXIELISAKITTR-Q-INFLIXIv296T抗英夫利昔单抗（类克）抗体ELISA试剂盒SHIKARIQ-ATIELISAKITTR-ATIv496TAdalimumab，商标Humira，阿达木单抗、修美乐阿达木单抗（修美乐）ELISA试剂盒SHIKARIQ-ADAELISAKITTR-ADAv196T抗阿达木单抗（修美乐）抗体ELISA试剂盒SHIKARIS-ATAELISAKITTR-A-ADAv196TEtanercept，商标Enbrel、Altebrel，依那西普、恩利依那西普（恩利）ELISA试剂盒SHIKARIQ-ETAELISAKITTR-ETAv196T抗依那西普（恩利）抗体ELISA试剂盒SHIKARIS-ATEELISAKITTR-AETAv296T人肿瘤坏死因子及受体TNF-αELISA试剂盒SHIKARIQ-TNFELISAKITTR-TNFv196TTNF-RII（p75/80kDa）ELISA试剂盒SHIKARIQ-sTNF-RIIELISAKITTR-sTNF-RIIv196TBevacizumab，商标Avastin，阿瓦斯汀、贝伐单抗、安维汀、癌思停贝伐单抗（安维汀）ELISA试剂盒SHIKARIQ-BEVAELISAKITTR-BEVAv196T抗贝伐单抗（安维汀）抗体ELISA试剂盒SHIKARIS-ATBELISAKITTR-ABEVAv196TRituximab，商标Rituxan、Mabthera，利妥昔单抗、美罗华、利克散、贺普丁、莫瘤利妥昔单抗（美罗华）ELISA试剂盒SHIKARIQ-RITUXELISAKITTR-RTXv196T抗利妥昔单抗（美罗华）抗体ELISA试剂盒SHIKARIS-ATRELISAKITTR-ARTXv196TTrastuzumab，商标Herclon,、Herceptin，曲妥珠单抗、赫赛汀、癌平曲妥珠单抗（赫赛汀）ELISA试剂盒SHIKARIQ-TRASELISAKITTR-TRASv196T抗曲妥珠单抗（赫赛汀）抗体ELISA试剂盒SHIKARIS-ATTELISAKITTR-ATRASv196T我们公司Zda优势是强大的采购，1：基本什么都能进口，血清，抗体，耗材，还有部分限制进口的，2：货品全，现经营过700多个品牌，基本所有生物试剂耗材都可以进口，特别是冷偏的产品那就更有优势，3：提供加急服务，一般1-2周到货，超过时限加急费全免4：价格公道，绝大部分价格有优势，当然不能保证1**%产品都是价格Zdi,因为价格Zdi意味着没有服务.5：良好的信誉，大部分客户我们提供货到付款服务，客户包括清华，北大交大复旦，中山等100多所大学，ROCHE，阿斯利康，国药，fisher等500多家公司6：我们还是Santa,AdvancedBiotechnologiesInc,Sorachim,bangs,BBInternational,crystalchem,dianova,FDNeurotechnologies,Inc.Dako,Inc,GePromegaridege,GlycotopeBiotechnologyGmbH;iduron,InnovativeResearchofAmerica,Ludger,neuroprobe,Sorachim,Polysciences,prospecbi,QA-BIO,quickzyme,FULLERLABS,INC,sterlitech；sysy,TriLinkBioTechnologies,Inc；worthington-biochem,zyagen等几十家国外公司授权代理。7：我们还是invitrogen,qiagen,Sorachimam,sigma;Promega,roche,merck,rnd,BD,GE,pierce,BioLegend等知名批发，欢迎合作。上海起发实验试剂有限公司联系人：杨建辉400电话：4006551678办公电话：021-50724187传真：021-50724961*8006手机：15921799099企业QQ:4006551678网址:http://www.qfbio。。ｃｏｍ/地址：上海市浦东新区晨阳路225弄东方现代商业广场46号303室(近东亭路)